Adare Pharma Solutions: Integrated End-To-End CDMO Solutions…From Start To Finish

Article

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with expertise in complex oral formulations. Our specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactures more than 45 products sold by customers worldwide.

Current Time 0:00
Duration 3:40
Loaded: 4.47%
Stream Type LIVE
Remaining Time 3:40
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Adaptdose White Paper

    Adaptdose™ allows drug developers to quickly create custom oral delivery systems and reduce time to market by eliminating the need to reformulate after Phase I in many cases.

    DOWNLOAD

    Duragran White Paper

    DuraGran® reduces the amount of excipients and/or process steps used to build beads or controlled release granules, and for higher concentration doses can spheronization and extrusion steps typically used.
    DOWNLOAD

    Adare Pharma Solutions Interactive Brochure

    This interactive brochure allows you to click through and learn more about all of Adare Pharma Solutions' major service offerings, technology platforms, and global facilities.
    DOWNLOAD

    Recent Videos
    Industry Outlook 2025: European Political Impacts on the Supply Chain
    Industry Outlook 2025: European Political Impacts on the Supply Chain
    AAPS National Biotechnology Conference 2025: High-Concentration Biologics
    AAPS National Biotechnology Conference 2025: High-Concentration Biologics
    Industry Outlook 2025: The Future of Technology in the Biopharma Industry
    Industry Outlook 2025: The Future of Technology in the Biopharma Industry
    AAPS National Biotechnology Conference 2025: AAV Vector Production
    AAPS National Biotechnology Conference 2025: AAV Vector Production
    Gaylord Chemical is Now gChem
    Gaylord Chemical is Now gChem
    BioDuro is Redefining CRDMO Partnerships With End-to-End Innovation
    BioDuro is Redefining CRDMO Partnerships With End-to-End Innovation
    Industry Outlook 2025: European Geopolitical Impact on Pharma
    Industry Outlook 2025: European Geopolitical Impact on Pharma
    Behind the Headlines Episode 16: NIH Funding, Re-Shoring, Tariffs, and Cell and Gene Therapies
    Behind the Headlines Episode 16: NIH Funding, Re-Shoring, Tariffs, and Cell and Gene Therapies
    Industry Outlook 2025: Political Implications for Pharma
    Industry Outlook 2025: Political Implications for Pharma
    Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
    Drug Digest: Keeping Pace with Progressive Technologies in Biopharma Development
    Related Content
    Coronavirus Covid-19 background - 3d rendering | Image Credit: © Production Perig - stock.adobe.com

    EMA Recommends Update to COVID-19 Vaccines for 2025-26 Campaign

    Patrick Lavery
    May 19th 2025
    Article

    The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.

    Site Logo

    Transformations in Drug Development for Cell and Gene Therapies

    PPD;Thermo Fisher Scientific
    March 28th 2025
    Podcast

    As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

    Darmstadt, Germany - November 10, 2021: A building at the headquarters of science and technology company Merck KGaA. | Image Credit: © Anne Czichos - stock.adobe.com

    Merck KGaA Becomes Strategic Partner in Peregrine Ventures’ Incentive Incubator

    Patrick Lavery
    May 15th 2025
    Article

    Merck will have early-stage opportunities to help startups set up for future success in the pharmaceutical and life sciences fields.

    Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

    Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

    PPD;Thermo Fisher Scientific
    March 28th 2025
    Podcast

    As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

    Pharmacy, hands and prescription medicine for customer with paper bag for healthcare, drugs and pharmaceutical. Closeup of a pharmacist or medical worker with person in drugstore for retail service | Image Credit: © Azee Jacobs/peopleimages.com - stock.adobe.com

    Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients

    Patrick Lavery
    May 13th 2025
    Article

    According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.

    Feb 2, 2020 South San Francisco / CA / USA - Genentech headquarters in Silicon Valley; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009 | Image Credit: © Sundry Photography - stock.adobe.com

    Genentech and Roche Expand US Footprint with New North Carolina Manufacturing Facility

    Patrick Lavery
    May 13th 2025
    Article

    The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.